Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kigelia africana fruit extract (KAE) is a botanical derivative obtained from the fruit of the African "sausage tree," a plant deeply rooted in traditional African medicine for treating skin-related conditions and infections. The extract is characterized by a rich profile of bioactive secondary metabolites, including naphthoquinones (such as lapachol), iridoids, and phenolic acids. In contemporary pharmacological research, KAE has demonstrated significant antineoplastic potential, particularly in colorectal carcinoma models, where it modulates signaling pathways associated with cell survival, apoptosis, and metastasis. It has been shown to suppress proteins linked to therapy resistance and exhibits synergistic cytotoxicity when combined with standard chemotherapeutic agents like cisplatin. Beyond oncology, the extract is widely utilized in the cosmetic and nutraceutical industries for its antioxidant, anti-inflammatory, and skin-firming properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kigelia africana fruit extract.